medicare coverage of glp-1 does cover for diabetes MCT2D CMS has announced important updates

In the Phase 3 REDEFINE 1 trial, cagrilintide monotherapy achieved 11.8% average weight loss over 68 weekscomparable to semaglutide but with a notably lower incidence of nausea and vomiting, making it a potential option for patients who dont tolerate GLP-1 medications well

This creates a risk that Pfizers new launches may underperform

Providers who offer year-round activity planning that accounts for these realities deliver better results

Reduced gastrointestinal motility and altered drug absorption may require dose adjustments of medications including warfarin, direct oral anticoagulants, opioids, and antiepileptic agents